Dr Reddy’s Laboratories has announced a delay in the commercial supplies of semaglutide, a key ingredient in diabetes and obesity medicines, due to an issue related to the active pharmaceutical ingredient used in the drug.
The company stated that certain batches of semaglutide were found to be out of specification, and it is investigating the root cause and taking measures to ensure product quality. Dr Reddy’s has launched its semaglutide injection, Obeda, in India to treat diabetes.
More than half a dozen Indian drugmakers have launched lower-cost copies of Novo Nordisk’s Ozempic and Wegovy, vying for a share of the fast-growing global obesity treatment market. Demand for the drugs has plateaued in June, according to research firm Pharmarack.
Original reporting: Appleton, WI News Feed (HLL/CB) — read the source article.
